DRUG DELIVERY TO THE BRAIN USING NOVEL NANOMATERIALS

使用新型纳米材料将药物输送到大脑

• 批准号: 7960123
• 负责人: Kristi Lynn Haik
• 金额: $ 1.7万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-22 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7960123
• 关键词: Address; Adult; Architecture; Biomedical Research; Biotin; Blood - brain barrier anatomy; Brain; Brain Diseases; Cells; Chronic; Computer Retrieval of Information on Scientific Projects Database; Dendrimers; Diagnosis; Disease; Drug Delivery Systems; Funding; Generations; Grant; Injury; Institution; Pharmaceutical Preparations; Research; Research Personnel; Resources; Shapes; Source; Surface; Testing; Toxic effect; United States National Institutes of Health; design; immunogenicity; nanomaterials; nanoscience; novel; seal; therapy development

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. More than one million adults are diagnosed annually with chronic brain diseases, disorders or injuries. Unfortunately, a majority of the therapies developed may only be administered by injecting them directly into the brain because the blood brain barrier (BBB), a tight seal of various cells, impedes delivery of most drugs. Nanoscience provides unique opportunities to address this issue. Dendrimers are highly customizable nanopolymers that appeal to biologists and chemists because of their precise architecture, size/shape control, high uniformity/purity, high loading capacity, low toxicity and low immunogenicity. These qualities also make them ideal for use in drug delivery. The purpose of this proposal is to design novel dendrimers that cross the BBB and to test their efficacy in doing so. Our hypothesis is that by modifying surface groups of generation 4 PAMAM and generation 3 Priostar" dendrimers with substances known to cross the BBB, we may create potential drug delivery vehicles that may use endogenous transporter mechanisms to gain entrance to the brain. In this study, we will synthesize Priostar" dendrimers with a biotin surface groups.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 每年有超过一百万成年人被诊断患有慢性脑部疾病、紊乱或损伤。 不幸的是，大多数开发的疗法只能通过直接注射到大脑中来施用，因为血脑屏障（BBB）是各种细胞的紧密密封，阻碍了大多数药物的输送。 纳米科学为解决这个问题提供了独特的机会。树枝状聚合物是高度可定制的纳米聚合物，因其精确的结构、尺寸/形状控制、高均匀性/纯度、高负载能力、低毒性和低免疫原性而吸引了生物学家和化学家。这些品质也使它们非常适合用于药物输送。该提案的目的是设计穿过 BBB 的新型树枝状聚合物并测试其功效。我们的假设是，通过用已知可穿过 BBB 的物质修饰第 4 代 PAMAM 和第 3 代 Priostar” 树枝状聚合物的表面基团，我们可能会创造出潜在的药物输送载体，利用内源性转运机制进入大脑。在这项研究中，我们将合成具有生物素表面基团的 Priostar” 树枝状聚合物。